扫码关注我们
微信二维码

Endocrinology-Hormones

Small molecules play a pivotal role in Endocrinology Research. These are low molecular weight compounds that have a significant impact on the endocrine system, hormones, and their receptors. Here are some key aspects of how small molecules are involved in this field:

  • Hormone Mimetics and Inhibitors: Small molecules are used to develop synthetic compounds that mimic the actions of hormones or inhibit their effects. For example, drugs like metformin for diabetes management and selective estrogen receptor modulators (SERMs) for breast cancer treatment are used to either mimic or block hormonal activity.
  • Receptor Modulation: Small molecules can bind to hormone receptors and modulate their activity. This is crucial in developing drugs that target specific hormone receptors, like the use of small molecule agonists and antagonists to regulate thyroid hormone receptors.
  • Metabolism Regulation: Endocrinology research often focuses on metabolism and how hormones like insulin regulate it. Small molecules are employed to understand and develop drugs targeting enzymes involved in metabolism, such as glucagon-like peptide-1 (GLP-1) agonists for diabetes treatment.
  • Steroid Hormone Production: Small molecules may be utilized to influence the production of steroid hormones in the adrenal glands or gonads. This is essential for conditions like Cushing's syndrome or polycystic ovary syndrome (PCOS).
  • Hormone Assays: In laboratory research, small molecules are used as tracers or markers in hormone assays. For instance, small molecule fluorophores can be attached to antibodies to detect hormone levels in blood samples.

Drug Development: Endocrinology research relies on small molecules as potential drug candidates. Researchers design and test small molecules for their effectiveness in modulating hormonal pathways, with the goal of developing new therapies for endocrine disorders.
In summary, small molecules are indispensable tools in Endocrinology Research, enabling scientists to better understand the endocrine system's intricacies and develop novel treatments for a wide range of hormonal disorders and conditions. Their versatility and specificity make them valuable assets in advancing our knowledge of endocrinology and improving patient care.


Endocrinology Disease Products


Endocrinology Research Products

Kisspeptin Receptor

Leptin Receptors

Melanocortin (MC) Receptors

Mineralocorticoid Receptors

Ghrelin Receptors

Natriuretic Peptide Receptors

NPY Receptors

Motilin Receptor

PTH Receptor

Shop By

8 Items

per page
Set Descending Direction
目录号
产品名
应用
产品描述
文献引用
  1. Estrogen receptor degrader

    Elacestrant (RAD1901) 是一种口服可用的选择性雌激素受体降解剂(SERD),其对 ERα 和 ERβ 的 IC50 分别为 48 nM 和 870 nM。
  2. Estrogen receptor degrader

    Brilanestrant (GDC-0810, ARN-810) 是一种强效的 ER-α 结合剂(ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM),是一种完全的转录拮抗剂,没有激动作用,并在 ER-α 降解(EC50 = 0.7 nM)和 MCF-7 乳腺癌细胞存活率(IC50 = 2.5 nM)测试中显示出良好的效力和效果,对其他核激素受体具有良好的选择性。
  3. SERD/SERM

    RAD1901 是一种口服可用的、选择性雌激素受体降解剂(SERD)和选择性雌激素受体调节剂(SERM),具有潜在的抗肿瘤和类雌激素活性。
  4. PROTAC ER Degrader-3 是合成 PAC 的中间体。PAC 包含 ADCs 连接器和 PROTACs,与抗体结合。PAC 来自专利 WO2017201449A1,化合物 LP2。与抗体结合的 PAC 是比 PROTAC(未结合抗体)更显著的雌激素受体-α(ERα)降解剂。
  5. ERRα Degrader

    PROTAC ERRα Degrader-1 包含一个 MDM2 配体结合基团、一个连接器和一个与雌激素相关受体α(ERRα)结合的基团。PROTAC ERRα Degrader-1 是一种雌激素相关受体α(ERRα)降解剂。
  6. estrogen receptor degrader

    LSZ-102 是一种强效的、口服生物利用度高的选择性雌激素受体降解剂,其 IC50 为 0.2 nM。
  7. estrogen receptor degrader

    GDC-0927 Racemate (SRN-927 Racemate) 是一种雌激素受体降解剂,能强效抑制 ER-α 活性,其 IC50 为 0.2 nM,用于研究与 ER 相关的疾病。
  8. Estrogen receptor degrader

    SAR439859 是一种口服可用的非甾体选择性雌激素受体降解剂/下调剂(SERD)。

8 Items

per page
Set Descending Direction
苏ICP备14027875号-1